[go: up one dir, main page]

PE20050324A1 - Derivados de anilida substituida como ligandos del receptor de tiroides - Google Patents

Derivados de anilida substituida como ligandos del receptor de tiroides

Info

Publication number
PE20050324A1
PE20050324A1 PE2004000094A PE2004000094A PE20050324A1 PE 20050324 A1 PE20050324 A1 PE 20050324A1 PE 2004000094 A PE2004000094 A PE 2004000094A PE 2004000094 A PE2004000094 A PE 2004000094A PE 20050324 A1 PE20050324 A1 PE 20050324A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
hydroxy
methylethyl
phenoxy
Prior art date
Application number
PE2004000094A
Other languages
English (en)
Inventor
William N Washburn
Wei Meng
Denis E Ryono
Thomas Ericsson
Neeraj Garg
Mahmoud Rahimi-Ghadim
Bruce A Ellsworth
Johan Malm
Original Assignee
Karobio Ab
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karobio Ab, Bristol Myers Squibb Co filed Critical Karobio Ab
Publication of PE20050324A1 publication Critical patent/PE20050324A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE ANILIDA SUBSTITUIDA DE FORMULA I EN DONDE, X ES O, Se, S, SULFONILO, ENTRE OTROS; R1 ES H, HALOGENO, CF3, ALQUILO C1-C6; R2 ES HALOGENO, CF3, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R3 ES H, ALQUILO, BENCILO, AROILO o ALCANOILO; R4 ES HALOGENO o ALQUILO; R5 ES H, HALOGENO o ALQUILO; R6 Y R7 SON H, HALOGENO, CIANO, ALQUILO C1-C4 o CICLOALQUILO C3-C6, DONDE AL MENOS UNO DE R6 Y R7 NO ES H; R8 Y R9 SON H, HALOGENO, ALCOXI, HIDROXI, CIANO, ENTRE OTROS; CON TAL QUE NO MAS QUE UNO DE R6, R7, R8 Y R9 ES H; R10 ES H o ALQUILO; R11 ES CO2R14; R12 Y R13 SON H, HALOGENO o ALQUILO; R14 ES H, ALQUILO, CICLOALQUILO, ARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 3-[N-[3,5-DIBROMO-4-[4-HIDROXI-3-(1-METILETIL-5-METIL)-FENOXI]-2-METILFENIL]AMINO]-3-OXOPROPANOICO; ACIDO 3-[N-[2,3,5-TRICLORO-4-[4-HIDROXI-3-(1-METILETIL-5-METIL)-FENOXI]FENIL]AMINO]-3-OXOPROPANOICO; ACIDO 3-[N-[3,5-DICLORO-4-[4-HIDROXI-3-(1-METILETIL-5-METIL)-FENOXI]-2-METILFENIL]AMINO]-3-OXOPROPANOICO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA FORMULACION FARMACEUTICA. ESTOS COMPUESTOS SON LIGANDOS DEL RECEPTOR DE LA HORMONA DE TIROIDES Y SON UTILES PARA PREVENIR, INHIBIR O TRATAR ENFERMEDADES O TRASTORNOS ASOCIADOS CON LA DISFUNCION METABOLICA, O LOS CUALES DEPENDEN DE LA EXPRESION DE UN GEN REGULADO POR (3,5,3'-TRIYODO-L-TIRONINA (T3)
PE2004000094A 2003-01-24 2004-01-26 Derivados de anilida substituida como ligandos del receptor de tiroides PE20050324A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44242103P 2003-01-24 2003-01-24

Publications (1)

Publication Number Publication Date
PE20050324A1 true PE20050324A1 (es) 2005-05-12

Family

ID=32825218

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000094A PE20050324A1 (es) 2003-01-24 2004-01-26 Derivados de anilida substituida como ligandos del receptor de tiroides

Country Status (8)

Country Link
US (1) US7342127B2 (es)
EP (1) EP1601641A4 (es)
JP (1) JP2006516623A (es)
AR (1) AR042909A1 (es)
CL (1) CL2004000102A1 (es)
PE (1) PE20050324A1 (es)
TW (1) TW200504021A (es)
WO (1) WO2004067482A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3092901A (en) * 2000-02-17 2001-08-27 Bristol Myers Squibb Co Aniline-derived ligands for the thyroid receptor
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
GB0606201D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Improved crytalline material
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
WO2007132475A1 (en) * 2006-05-15 2007-11-22 Cadila Healthcare Limited Selective tr-beta 1 agonist
NZ576324A (en) * 2006-10-31 2011-08-26 Cadila Healthcare Ltd Selective tr-beta 1 agonist
CA2741517A1 (en) 2008-10-27 2010-05-06 Cadila Healthcare Limited Thyroid receptor ligands
WO2010086878A2 (en) 2009-01-09 2010-08-05 Cadila Healthcare Limited Thyroid receptor modulators
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション ＰＰＡＲδアゴニストの胎児再プログラミング用途
JP2020500199A (ja) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
CN113292391B (zh) * 2021-06-11 2024-04-02 江西扬帆新材料有限公司 2-溴碘苯的制备方法
US20230357125A1 (en) * 2022-05-06 2023-11-09 AMPAC Fine Chemicals Process for Catalytic Reduction of Nitro Compounds to Amines

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3239345A (en) * 1965-02-15 1966-03-08 Estrogenic compounds and animal growth promoters
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4027009A (en) * 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
US4036979A (en) * 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
JPS5612114B2 (es) * 1974-06-07 1981-03-18
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4378785A (en) * 1981-05-28 1983-04-05 Dale Fleischmann Solar heating system
US4448784A (en) * 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en) * 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
US4586237A (en) * 1983-09-28 1986-05-06 Usm Corporation Drive mechanism for a cut and clinch unit
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
HU198005B (en) 1984-12-04 1989-07-28 Sandoz Ag Process for producing mevqlolakton, derivatives, its indene-analogues and pharmaceutical compositions containing them
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
KR900001212B1 (ko) 1985-10-25 1990-02-28 산도즈 파마슈티칼스 코오포레이숀 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도
DE3543999A1 (de) * 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
PT87539B (pt) 1987-05-22 1992-09-30 Squibb & Sons Inc Processo para a preparacao de inibidores da reductase de hmg-coa contendo fosforo e novos intermediarios
US4759923A (en) * 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4871721A (en) * 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
US4924024A (en) * 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
NO177005C (no) * 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
ATE122357T1 (de) 1988-01-28 1995-05-15 Polygen Holding Corp Polypeptide mit hormonwachstumsbefreiender wirkung.
JPH03502326A (ja) 1988-01-28 1991-05-30 ポリゲン　ホールディング　コーポレイション 成長ホルモン放出活性を有するポリペプチド化合物類
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) * 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE69314718T2 (de) * 1992-07-21 1998-02-26 Ciba Geigy Ag Oxamidsäure-Derivate als hypocholesterämische Mittel
US5712396A (en) * 1992-10-28 1998-01-27 Magnin; David R. α-phosphonosulfonate squalene synthetase inhibitors
CA2102591C (en) 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US5594016A (en) * 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
SG45369A1 (en) * 1993-01-19 1998-10-16 Warner Lambert Co Stable oral ci-981 formulation and process of preparing same
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) * 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5385929A (en) * 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
JP2814950B2 (ja) 1994-05-11 1998-10-27 田辺製薬株式会社 血糖降下剤
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
JP3065235B2 (ja) 1995-11-07 2000-07-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3059088B2 (ja) 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3006513B2 (ja) 1995-11-07 2000-02-07 田辺製薬株式会社 医薬組成物
JP3034192B2 (ja) 1995-11-07 2000-04-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
EP0873361B1 (en) 1995-12-13 2006-11-02 The Regents Of The University Of California Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand
US5770615A (en) * 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5962440A (en) * 1996-05-09 1999-10-05 Bristol-Myers Squibb Company Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en) * 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en) * 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
DK0850948T3 (da) 1996-12-26 2002-07-29 Tanabe Seiyaku Co Propiophenonderivater og fremgangsmåde til fremstilling deraf
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
JPH10245391A (ja) 1997-03-03 1998-09-14 Dainippon Ink & Chem Inc ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
US6803357B1 (en) 1998-02-02 2004-10-12 New England Medical Center Hospitals, Inc. Method of regulating glucose metabolism, and reagents related thereto
WO1999046272A1 (en) 1998-03-09 1999-09-16 Fondatech Benelux N.V. Serine peptidase modulators
WO1999048859A1 (en) * 1998-03-20 1999-09-30 Bristol-Myers Squibb Company Aryloxyanilides and related compounds
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
IL140622A0 (en) 1998-07-06 2002-02-10 Bristol Myers Squibb Co Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
CO5150159A1 (es) * 1998-12-04 2002-04-29 Bristol Myers Squibb Co Derivados de 4-arilquinolin-2-ona 3-substituida como moduladores de los canales de potasio
AU3092901A (en) * 2000-02-17 2001-08-27 Bristol Myers Squibb Co Aniline-derived ligands for the thyroid receptor
WO2001070687A1 (de) 2000-03-23 2001-09-27 Bayer Aktiengesellschaft Indole zur behandlung von krankheiten die mit schilddrüsenhormonen behandeln werden können
US6664291B2 (en) * 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
AU2001237665A1 (en) 2000-03-31 2001-10-08 Pfizer Products Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
WO2001085670A1 (en) 2000-05-12 2001-11-15 Kissei Pharmaceutical Co., Ltd. Malonanilic acid derivatives, medicinal compositions containing the same and use thereof
DE10024939A1 (de) 2000-05-19 2001-11-29 Bayer Ag Neue Diphenylmethanderivate für Arzneimittel
US6395784B1 (en) 2000-06-07 2002-05-28 Bristol-Myers Squibb Company Benzamide ligands for the thyroid receptor
CA2433100A1 (en) 2000-12-27 2002-07-04 Helmut Haning Indole derivatives as ligands of thyroid receptors
IL157031A0 (en) 2001-02-08 2004-02-08 Karobio Ab Thyroid receptor ligands
DE10122443A1 (de) 2001-05-09 2002-11-14 Bayer Ag Amido-Diphenyl-Derivate
JP4225791B2 (ja) 2001-05-18 2009-02-18 キッセイ薬品工業株式会社 肝癌の予防または再発抑制剤
ES2253495T3 (es) 2001-09-26 2006-06-01 Pfizer Products Inc. Acidos indol carboxilicos como ligandos de receptores tiroideos.
GB0219022D0 (en) 2002-08-15 2002-09-25 Karobio Ab Novel thyromimetic compounds

Also Published As

Publication number Publication date
EP1601641A4 (en) 2007-03-21
AR042909A1 (es) 2005-07-06
US7342127B2 (en) 2008-03-11
JP2006516623A (ja) 2006-07-06
CL2004000102A1 (es) 2005-01-07
EP1601641A2 (en) 2005-12-07
WO2004067482A3 (en) 2004-10-21
TW200504021A (en) 2005-02-01
WO2004067482A2 (en) 2004-08-12
US20040180940A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
PE20050324A1 (es) Derivados de anilida substituida como ligandos del receptor de tiroides
CA3160518C (en) GLP-1 RECEIVER AGONIST AND ITS USE
UY26043A1 (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos
MA64510B1 (fr) Agonistes du récepteur glp-1 et leurs utilisations
MX2022013842A (es) Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso.
PE20091099A1 (es) Derivados de aminobenzamida como agentes utiles para controlar parasitos animales
PE20230239A1 (es) Derivado de arilamida con actividad antitumoral
ECSP055636A (es) Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa
UY26581A1 (es) Ligandos derivados de anilina para el receptor de la tiroides
PE20190503A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
PE20040775A1 (es) DERIVADOS DE INDOL COMO AGONISTAS DE ADRENORECEPTORES ß2
AR039566A1 (es) Inhibidores de la histona deacetilasa, composicion farmaceutica que los contiene y sus procesos de preparacion
AR011776A1 (es) UN ACOMPOSICIoN FARMACÉUTICA PARA TRATAR TRASTORNOS DE LA APETENCIA POR EL CONSUMO DE CARBOHIDRATOS O ALCOHOLES
LT2006017A (en) 2-(quinoxalin-5-ylsulfonylamino)-benzamide compounds as cck2 modulators
PE20040672A1 (es) Derivados de fenil o heteroaril amino alcano
PE20060357A1 (es) Compuestos y composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
AR071548A1 (es) Amidas de acido 3-substituido-4-oxo-3, 4-dihidro-imidazo[5, 1-d]1, 2, 3, 5-tetracina-8-carboxilico, un metodo para su preparacion e intermediarios de su sintesis, una composicion farmaceutica que las comprende y su uso en la fabricacion de medicamentos para el tratamiento de diversos tipos de cancer
CO2021010611A2 (es) Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
ZA202207541B (en) Substituted triazinones as thyroid hormone receptor agonists
EP3921309A1 (en) Quinolin-4-one and 4(1h)-cinnolinone compounds and methods of using same
AR061973A1 (es) Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos
AR072611A1 (es) Compuestos de 3-(fenoxifenilmetil)pirrolidina, un metodo para su preparacion, intermediario de sintesis y su proceso de obtencion, composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de 5-ht y ne.
WO2018154118A2 (en) Novel aromatic compounds
PE20191646A1 (es) Derivados pirazol [1,5-a] pirimidina sustituidos con aliciclicos farmacologicamente activos
PE20040799A1 (es) Derivados de tetrahidroquinolina como moduladores del receptor fhs

Legal Events

Date Code Title Description
FC Refusal